Nanochap raises $75.2M Series C extension to advance vision brain-computer interface
What's the deal? Hangzhou-based Nanochap raised US$68.8M in a Series C extension led by Gaorong Ventures, the company announced in November. New backers included PICC Equity, Monolith CapitalDealroom has a profile for this one. Try Dealroom →, C&D Emerging Industry Investment, Orient Fortune Capital, Danhe Capital, and Hangzhou Industrial Investment Group, with existing investors Legend Capital and others putting in additional money.
What's the endgame? Founded in 2014, Nanochap develops, manufactures, and sells brain-computer interface and neuro-biological chips. Its focus is vision restoration — a clinically demanding path within the sector with clear demand.
Why now? The round follows a US$41.3M strategic financing in May, signalling investors doubling down in a short window. That earlier raise was earmarked for clinical trials and technology iteration; the company's retinal-pathway product has already begun human trials, while its visual-cortex approach remains at an earlier stage.
What could go wrong? Efficacy, safety, and trial progress all remain unproven, and commercialisation is still distant. Vision restoration carries high clinical hurdles, and funding and investor confidence do not guarantee regulatory approval.
The signal: International competition is heating up — Neuralink's Blindsight has won a US Food and Drug Administration breakthrough device designation, though such status does not equal market clearance. Nanochap's raise mainly buys time and capital to push clinical validation in a race China is now contesting.
Read more: sohu.com
Image credit: Generated with Gemini
